Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Skin Diseases Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Molecular Breast Imaging and Digital Breast Tomosynthesis in Screening Patients With Dense Breast Tissue

NCT03220893
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Digital Breast Tomosynthesis (DBT), Scintimammography
Procedure · Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years to 75 Years · Female only
Enrollment
3,023 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2024
U.S. locations
5
States / cities
Detroit, Michigan • Rochester, Minnesota • Toledo, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Jul 22, 2026, 2:09 AM EDT
Completed Phase 2 Interventional Results available

Dose-Finding Study of CD07805/47 Topical Gel in Subjects With Erythematotelangiectatic Rosacea

NCT00989014
View directory record Official record
Conditions
Erythematotelangiectatic Rosacea
Interventions
CD07805/47, CD07805/47 placebo
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
5
States / cities
Hot Springs, Arkansas • Fort Washington, Pennsylvania • Austin, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Jul 22, 2026, 2:09 AM EDT
Not yet recruiting Not applicable Interventional

A Pilot Study Assessing Myokines During an EXErcise Regimen After Treatment for Breast Cancer

NCT07698314
View directory record Official record
Conditions
Cancer, Breast Cancer
Interventions
Conditioning Resistance Training, Strength Resistance Training, Hypertrophy Resistance Training
Behavioral
Lead sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Other
Eligibility
20 Years to 89 Years · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Jul 22, 2026, 2:09 AM EDT
Withdrawn Phase 4 Interventional

Metformin Use to Reduce Disparities in Newly Diagnosed Breast Cancer

NCT04741204
View directory record Official record
Conditions
Breast Cancer Stage, Insulin Resistance, Racial Bias
Interventions
Metformin Extended Release Oral Tablet
Drug
Lead sponsor
Woman's
Other
Eligibility
18 Years to 80 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 5, 2023 · Synced Jul 22, 2026, 2:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Improving Compliance With Medical Testing Guidelines

NCT02430948
View directory record Official record
Conditions
Breast Cancer, Cervical Cancer, Prostate Cancer, Colon Cancer, Lung Cancer
Interventions
Color-coded materials, Academic detailing, Standard support, No academic detailing
Other
Lead sponsor
Beth Israel Medical Center
Other
Eligibility
30 Years to 89 Years
Enrollment
218 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 25, 2019 · Synced Jul 22, 2026, 2:09 AM EDT
Completed No phase listed Observational

Efficacy Verification in Early Diagnosis and Management of Lymphedema Through Home Body Water Analyzer

NCT06580743
View directory record Official record
Conditions
Breast Cancer
Interventions
No intervention
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Jul 22, 2026, 2:09 AM EDT
Recruiting Phase 2 Interventional

Predicting Response to Neoadjuvant Endocrine Therapy (Neo-PREDICT)

NCT06806930
View directory record Official record
Conditions
Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III, Carcinoma, Breast
Interventions
Neoadjuvant endocrine therapy
Drug
Lead sponsor
George Washington University
Other
Eligibility
21 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Jul 22, 2026, 2:09 AM EDT
Active, not recruiting Phase 1 Interventional

First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer

NCT06239467
View directory record Official record
Conditions
Advanced Cancer, Breast Cancer, Advanced Solid Tumors, PI3K Gene Mutation
Interventions
OKI-219, Fulvestrant, Trastuzumab, Tucatinib, Atirmociclib, Ribociclib
Drug
Lead sponsor
OnKure, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
12
States / cities
Encinitas, California • La Jolla, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 22, 2026, 2:09 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body

NCT06421636
View directory record Official record
Conditions
Non-Transfusion Dependent Beta-Thalassemia (NTDT)
Interventions
REGN7999, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Jul 22, 2026, 2:09 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

1470nm Laser for the Treatment of Androgenetic Alopecia and Scarring Alopecia

NCT05460611
View directory record Official record
Conditions
Scarring Alopecia, Androgenetic Alopecia
Interventions
Sciton HALO 1470nm Non-ablative laser
Device
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Elmsford, New York
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Jul 22, 2026, 2:09 AM EDT
Terminated No phase listed Observational

Patient Derived Breast Cancer Xenografts

NCT01750164
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Not listed
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated May 11, 2015 · Synced Jul 22, 2026, 2:09 AM EDT
Recruiting No phase listed Observational

A Study to Describe the Real-world Effectiveness, Safety and Patterns of Use of Dupilumab in Patients With Chronic Spontaneous Urticaria

NCT07316114
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
Dupilumab
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Jul 22, 2026, 2:09 AM EDT
Active, not recruiting Phase 1 Interventional

Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

NCT04013685
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Myelodysplastic Syndromes, Acute Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Chronic Myeloid Leukemia
Interventions
Orca-T
Biological
Lead sponsor
Orca Biosystems, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
21
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Jul 22, 2026, 2:09 AM EDT
Completed Phase 2 Interventional

Randomised Study to Compare the Efficacy of AZD6244 vs TMZ

NCT00338130
View directory record Official record
Conditions
Melanoma
Interventions
AZD6244, Temozolomide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
10
States / cities
Santa Monica, California • Aurora, Colorado • Miami Beach, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2014 · Synced Jul 22, 2026, 2:09 AM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Systemic Absorption of Dexamethasone Oral Rinse in Patients With Oral Lichen Planus

NCT06428630
View directory record Official record
Conditions
Oral Lichen Planus, Oral Lichenoid Reaction
Interventions
dexamethasone oral rinse
Drug
Lead sponsor
Tufts University
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Jul 22, 2026, 2:09 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Iontophoretic Application of Acyclovir Cream to Treat Recurrent Herpes Labialis

NCT00230867
View directory record Official record
Conditions
Herpes Labialis
Interventions
iontophoretic acyclovir
Device
Lead sponsor
Transport Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
26
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2006 · Synced Jul 22, 2026, 2:09 AM EDT
Completed Phase 3 Interventional

Chemotherapy in Treating Women With Breast Cancer That Can Be Surgically Removed

NCT00002707
View directory record Official record
Conditions
Breast Cancer
Interventions
Cyclophosphamide, Docetaxel, Doxorubicin, Tamoxifen
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
Female only
Enrollment
2,411 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2010
U.S. locations
134
States / cities
Huntsville, Alabama • Phoenix, Arizona • Greenbrae, California + 115 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2010 · Synced Jul 22, 2026, 2:09 AM EDT
Withdrawn Phase 2 Interventional

QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine

NCT03554109
View directory record Official record
Conditions
Triple Negative Breast Cancer (TNBC)
Interventions
Leucovorin, 5-Fluorouracil, Aldoxorubicin HCl, nab-Paclitaxel, ETBX-011, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, Avelumab, ALT-803, haNK, Cyclophosphamide, Doxorubicin HCL, paclitaxel
Drug · Biological
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
El Segundo, California
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Jul 22, 2026, 2:09 AM EDT
Completed Phase 2 Interventional Results available

A Vehicle Controlled Study to Evaluate Safety and Efficacy of Topical TMB-001 for Treatment of Congenital Ichthyosis

NCT04154293
View directory record Official record
Conditions
Congenital Ichthyosis
Interventions
Isotretinoin, Vehicle
Drug · Other
Lead sponsor
LEO Pharma
Industry
Eligibility
9 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
8
States / cities
Phoenix, Arizona • Palo Alto, California • New Haven, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 22, 2026, 2:09 AM EDT
Completed Phase 2 Interventional Results available

Fulvestrant With or Without Ganetespib in HR+ Breast Cancer

NCT01560416
View directory record Official record
Conditions
Breast Cancer
Interventions
Fulvestrant, Ganetespib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
5
States / cities
Boston, Massachusetts • Concord, New Hampshire • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Jul 22, 2026, 2:09 AM EDT
Terminated Phase 2Phase 3 Interventional

Trial With HuMax-CD4 in Participants With Rheumatoid Arthritis (RA) Failing Treatment With Methotrexate (MTX) and a TNF-alpha Blocker

NCT00042406
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Humax-CD4, Placebo
Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
50
States / cities
Montgomery, Alabama • Long Beach, California • Rancho Cucamonga, California + 45 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Jul 22, 2026, 2:09 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE

NCT06897930
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
AZD0120, Cyclophosphamide, Fludarabine
Biological · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
15
States / cities
San Francisco, California • Stanford, California • Tampa, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 22, 2026, 2:09 AM EDT
Active, not recruiting Phase 4 Interventional

A Study to Assess Sebaceous Gland Changes and Constituents of Sebum (Skin Oil) Induced by Clascoterone 1% Cream in Acne Patients

NCT06425900
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Winlevi (Clascoterone) cream 1%
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years to 35 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Jul 22, 2026, 2:09 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation

NCT04711109
View directory record Official record
Conditions
BRCA1 Mutation, Breast Cancer, Breast Diseases, Breast Neoplasms, Breast Carcinoma, Neoplasms
Interventions
Denosumab, Placebo, Quality-of-Life Assessment
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
25 Years to 55 Years · Female only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2033
U.S. locations
47
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 38 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Jul 22, 2026, 2:09 AM EDT